Liver Transplant Infection
9
1
1
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.1%
1 terminated out of 9 trials
66.7%
-19.8% vs benchmark
22%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant
Rezafungin Prophylaxis in Liver Transplant
Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen
Application of Nanopore Adaptive Sequencing
Pharmacological Study of Cefazolin Antibioprophylaxis in Liver Transplantation
Evaluation of Procalcitonin (PCT) as a Marker of Infection Post Living Donated Liver Transplant
Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation
Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients